Healthcare Industry News: Sanofi
News Release - October 24, 2013
Mallinckrodt Pharmaceuticals Announces Executive AppointmentsCompany Rounds Out Senior Leadership Team
DUBLIN--(Healthcare Sales & Marketing Network)--Mallinckrodt plc (MNK), a global specialty pharmaceuticals company, today announced three appointments to the Company’s senior management team. This will round out Mallinckrodt’s executive leadership and help drive the Company’s strategic focus toward growing its core business as a specialty pharmaceutical company. The newly appointed executives, all of whom are new to the Company, have served at some of the most prestigious companies in the health care and pharmaceutical field, and together they have a collective 70-plus years of experience in the industry.
Hugh O’Neill has joined the Company and will serve as Senior Vice President and President of Specialty Pharmaceuticals. Most recently, Mr. O’Neill held various commercial leadership positions at Sanofi, including Vice President, Commercial Excellence; General Manager; President of Sanofi Canada; and Vice President of Market Access and Business Development. He has also been in positions of leadership at Sandoz Pharmaceuticals, Forest Laboratories, Novartis Pharmaceuticals, and Pfizer.
Gary Phillips has joined the Company as Senior Vice President and Chief Strategy Officer, overseeing Strategy, Portfolio Management, Business Development and Licensing, Market Analytics and Alliance Management. Most recently, Dr. Phillips was head of Global Health and Healthcare Industries for the World Economic Forum in Geneva, Switzerland. Prior to that, he was President of Reckitt Benckiser Pharmaceuticals North America and President of US Pharmaceuticals and Surgical at Bausch & Lomb. He has also been in positions of leadership at Merck Serono, Novartis Pharmaceuticals, Wyeth-Ayerst, and Gensia Pharmaceuticals.
Mario Saltarelli has joined the Company as Senior Vice President and Chief Science Officer, and will lead the recently consolidated functions of Research and Development (R&D), Medical Affairs, and Regulatory Affairs. Dr. Saltarelli comes to Mallinckrodt having recently served as Senior Vice President, R&D, at Shire plc. Prior to that, he held positions of responsibility in R&D at Abbott Laboratories and Pfizer, and academic posts in the Department of Neurology at the Emory University School of Medicine in Atlanta.
“I'm delighted to welcome Hugh, Gary and Mario to Mallinckrodt and to our senior management team,” said Mark Trudeau, President and CEO of Mallinckrodt Pharmaceuticals. “Their combined years of experience and great strengths in their respective fields will help solidify our position as a science-based company, allow us to expand our core specialty pharmaceutical business, and position us to be more competitive in the marketplace. I am confident that, with these important additions to our senior leadership team, we are well positioned to unlock our potential to become a competitive leader in the specialty pharmaceutical space. I greatly look forward to working with them.”
Mallinckrodt is a leading global specialty pharmaceuticals business that develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents. The Company’s Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide with sales in roughly 70 countries. The company’s 2012 revenue totaled 2.1 billion. To learn more about Mallinckrodt, please visit www.mallinckrodt.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMallinckrodt Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft(R) Regenerative Tissue in Patients with Deep Partial-thickness Thermal Burns
Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part Of A Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases